Zomedica Corp. (ZOMDF)
| Market Cap | 102.31M +86.4% |
| Revenue (ttm) | 34.33M +24.7% |
| Net Income | -22.58M |
| EPS | -0.02 |
| Shares Out | 979.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 617,600 |
| Open | 0.1050 |
| Previous Close | 0.1050 |
| Day's Range | 0.1000 - 0.1070 |
| 52-Week Range | 0.0350 - 0.1580 |
| Beta | 1.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 29, 2026 |
About Zomedica
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. It offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. The company provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of p... [Read more]
Financial Performance
In 2025, Zomedica's revenue was $32.03 million, an increase of 17.39% compared to the previous year's $27.29 million. Losses were -$81.86 million, 74.2% more than in 2024.
Financial StatementsNews
Zomedica's PulseVet System Repeats as Official Shock Wave of the United States Eventing Association
Collaboration with USEA for Zomedica's PulseVet® shock wave system will increase brand awareness among Eventing enthusiasts. ANN ARBOR, MI / ACCESS Newswire / May 20, 2026 / Zomedica Corp. (OTCQB:ZOMD...
Zomedica Announces "Fifth Friday at Four" Webinar on May 29th: First Quarter 2026 Financial Results and a Deep Dive into the Companion Animal VetTech Market
May session to review Q1 2026 financial results alongside an investor-focused look at the companion animal market for veterinary technology and Zomedica's integrated small-animal portfolio, spanning i...
Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Zomedica surpasses $8 million in first quarter revenue for the first time and delivers record year-over-year revenue for 21st straight quarter. ANN ARBOR, MI / ACCESS Newswire / May 6, 2026 / Zomedica...
Zomedica Quarterly report: Q1 2026
Zomedica has published its Q1 2026 quarterly earnings report on May 6, 2026.
Zomedica Earnings release: Q1 2026
Zomedica released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Zomedica Proxy statement: Proxy filing
Zomedica filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Zomedica Proxy statement: Proxy filing
Zomedica filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale
April session to take investors inside Zomedica's manufacturing operations - showcasing quality systems, automation, and teams driving scalable product fulfillment providing substantial margins ANN AR...
Zomedica Proxy statement: Proxy filing
Zomedica filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform
Collaboration with one of the world's largest animal health companies expected to accelerate TRUFORMA adoption, expand installed base, and drive recurring diagnostic revenue ANN ARBOR, MI / ACCESS New...
Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity
Zomedica surpasses $10 million in quarterly revenue for the first time and delivers record year-over-year revenue for 20th straight quarter. ANN ARBOR, MI / ACCESS Newswire / March 16, 2026 / Zomedica...
Zomedica Slides: Investor presentation
Zomedica has posted slides in relation to its latest quarterly earnings report, which was published on March 16, 2026.
Zomedica Earnings release: Q4 2025
Zomedica released its Q4 2025 earnings on March 16, 2026, summarizing the period's financial results.
Zomedica Annual report: Q4 2025
Zomedica has published its Q4 2025 annual report on March 16, 2026.
Zomedica to Review 2025 Financial Results and Highlight Equine Market Opportunity During March 27th "Fourth Friday at Four" Investor Webinar
Webinar will include a review of full-year 2025 and fourth quarter 2025 financial results, a deep dive into the equine veterinary market and Zomedica's equine-focused product portfolio, along with a l...
Zomedica Transcript: Status update
R&D and product innovation remain central, with TRUFORMA, VetGuardian, and TRUVIEW platforms driving growth and market expansion. Financial performance is improving, with profitability targeted for 2027 and breakeven possible by end of 2026. Human health entry will focus on partnerships and contract manufacturing.
Zomedica Expands Distribution of TRUVIEW(R) Digital Microscopy Platform Through National Agreement with Moichor, a Leader in Veterinary Pathology
Partnership Expected to Accelerate System Placements and Support Recurring Consumables Revenue Growth ANN ARBOR, MI / ACCESS Newswire / February 25, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or ...
Zomedica Announces "Fourth Friday at Four" Webinar on February 27th Focused on Research & Development and Its Innovation Pipeline
February session to highlight how Zomedica's R&D strategy supports scalable growth and long-term shareholder value ANN ARBOR, MI / ACCESS Newswire / February 5, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Z...
Zomedica Expands its TRUVIEW(R) Microscopy Platform with AI Diagnostic Interpretation, Growing its Market Opportunity
AI-enabled hematology and cytology analysis improves diagnostic speed, consistency, and workflow efficiency for veterinary clinics ANN ARBOR, MI / ACCESS Newswire / January 23, 2026 / Zomedica Corp. (...
Zomedica Transcript: Status update
Digital innovation and AI are driving growth, with recurring consumable revenue at 70-73% and break-even targeted at $55M annualized revenue by 2027. TRUVIEW AI and PIMS integration are key product milestones, and new TRUFORMA assays will expand market reach in 2026.
Zomedica Enters Contract Manufacturing and Services Agreement with Rahm Sensor Development to Expand Revenue Streams Beyond Animal Health
Agreement leverages existing infrastructure to add contract-based revenue, improve asset utilization, support long-term cash flow and create shareholder value through diversified markets ANN ARBOR, MI...
Zomedica Announces "Fourth Friday at Four" Webinar on January 23rd Focused on Digital Innovation & Technology-Driven Growth
January session to highlight Zomedica's expanding digital capabilities and long-term innovation strategy ANN ARBOR, MI / ACCESS Newswire / January 14, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" o...
Zomedica Launches Next-Generation VETGuardian PLUS(TM) Monitor, Expanding Core Monitoring Platform in Growing Veterinary Market
New platform improves workflow efficiency, strengthens clinical confidence, and supports Zomedica's long-term growth strategy ANN ARBOR, MI / ACCESS Newswire / December 30, 2025 / Zomedica Corp. (OTCQ...
Zomedica Announces Collaboration with Prime Video as Assisi Loop(R) Products Appear in New Holiday Film Merv
The collaboration highlights Zomedica's commitment to expanding pet wellness education as Assisi Loop technology is featured in the highly anticipated movie Merv now available on Prime Video ANN ARBOR...
Zomedica Expands TRUFORMA(R) Diagnostic Menu with Launch of Equine Progesterone Assay
Newest assay expands TRUFORMA market opportunity by building on endocrinology foundation to address reproductive health in the equine segment ANN ARBOR, MI / ACCESS Newswire / December 4, 2025 / Zomed...